Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives $4.94 Average Target Price from Analysts

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been assigned an average rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.94.

CARM has been the topic of a number of recent analyst reports. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 30th. Robert W. Baird lowered shares of Carisma Therapeutics from an “outperform” rating to a “neutral” rating and cut their price target for the company from $10.00 to $1.00 in a report on Thursday, December 12th. HC Wainwright reaffirmed a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. BTIG Research downgraded shares of Carisma Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 10th. Finally, Evercore ISI reaffirmed an “in-line” rating and issued a $0.70 target price (down previously from $4.00) on shares of Carisma Therapeutics in a research report on Wednesday, December 11th.

Carisma Therapeutics Stock Down 7.9 %

Carisma Therapeutics stock opened at $0.46 on Friday. The company’s 50-day moving average price is $0.54 and its two-hundred day moving average price is $0.84. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 1.39. The stock has a market cap of $19.20 million, a price-to-earnings ratio of -0.29 and a beta of 1.56. Carisma Therapeutics has a 52 week low of $0.38 and a 52 week high of $2.77.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) EPS for the quarter, hitting the consensus estimate of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The firm had revenue of $3.39 million for the quarter. On average, analysts expect that Carisma Therapeutics will post -1.32 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Wexford Capital LP boosted its holdings in shares of Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after acquiring an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Carisma Therapeutics in the second quarter valued at $40,000. Finally, Barclays PLC grew its holdings in Carisma Therapeutics by 3,661,933.3% during the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after acquiring an additional 549,290 shares during the last quarter. 44.27% of the stock is currently owned by institutional investors and hedge funds.

About Carisma Therapeutics

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.